Severe Acute Respiratory Syndrome Coronavirus 2 Third Vaccine Immune Response in Multiple Sclerosis Patients Treated with Ocrelizumab

Livnat Brill; Catarina Raposo; Ariel Rechtman; Omri Zveik; Netta Levin; Esther Oiknine-Djian; Dana G. Wolf; Adi Vaknin-Dembinsky

doi:10.1002/ana.26343

Severe Acute Respiratory Syndrome Coronavirus 2 Third Vaccine Immune Response in Multiple Sclerosis Patients Treated with Ocrelizumab

Livnat Brill, Catarina Raposo, Ariel Rechtman, Omri Zveik, Netta Levin, Esther Oiknine-Djian, Dana G. Wolf, Adi Vaknin-Dembinsky

Institute for Medical Research Israel-Canada (IMRIC)

The Hebrew University of Jerusalem

Research output: Contribution to journal › Article › peer-review

Abstract

The introduction of a third-dose vaccination along with new variants of concern raises questions regarding serology and T-cell responses in patients with multiple sclerosis (pwMS) treated with B-cell depletion who develop attenuated humoral response to vaccines. The aim of this study was to longitudinally evaluate humoral and cellular response to SARS-CoV-2 mRNA vaccine in ocrelizumab-treated pwMS before and following a third vaccine dose. Following the third vaccine dose, patients who are low or nonresponders following initial vaccination did not increase antibody titers. In healthy controls and ocrelizumab-treated pwMS, cellular response decreased 6 months after initial vaccination and increased significantly after the third dose. ANN NEUROL 2022;91:796–800.

Original language	English
Pages (from-to)	796-800
Number of pages	5
Journal	Annals of Neurology
Volume	91
Issue number	6
DOIs	https://doi.org/10.1002/ana.26343
State	Published - Jun 2022

All Science Journal Classification (ASJC) codes

Neurology
Clinical Neurology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/ana.26343

Cite this

@article{35553a1b07004eb28297283af0f89e29,

title = "Severe Acute Respiratory Syndrome Coronavirus 2 Third Vaccine Immune Response in Multiple Sclerosis Patients Treated with Ocrelizumab",

abstract = "The introduction of a third-dose vaccination along with new variants of concern raises questions regarding serology and T-cell responses in patients with multiple sclerosis (pwMS) treated with B-cell depletion who develop attenuated humoral response to vaccines. The aim of this study was to longitudinally evaluate humoral and cellular response to SARS-CoV-2 mRNA vaccine in ocrelizumab-treated pwMS before and following a third vaccine dose. Following the third vaccine dose, patients who are low or nonresponders following initial vaccination did not increase antibody titers. In healthy controls and ocrelizumab-treated pwMS, cellular response decreased 6 months after initial vaccination and increased significantly after the third dose. ANN NEUROL 2022;91:796–800.",

author = "Livnat Brill and Catarina Raposo and Ariel Rechtman and Omri Zveik and Netta Levin and Esther Oiknine-Djian and Wolf, \{Dana G.\} and Adi Vaknin-Dembinsky",

note = "Publisher Copyright: {\textcopyright} 2022 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.",

year = "2022",

month = jun,

doi = "10.1002/ana.26343",

language = "الإنجليزيّة",

volume = "91",

pages = "796--800",

journal = "Annals of Neurology",

issn = "0364-5134",

publisher = "John Wiley \& Sons Inc.",

number = "6",

}

TY - JOUR

T1 - Severe Acute Respiratory Syndrome Coronavirus 2 Third Vaccine Immune Response in Multiple Sclerosis Patients Treated with Ocrelizumab

AU - Brill, Livnat

AU - Raposo, Catarina

AU - Rechtman, Ariel

AU - Zveik, Omri

AU - Levin, Netta

AU - Oiknine-Djian, Esther

AU - Wolf, Dana G.

AU - Vaknin-Dembinsky, Adi

PY - 2022/6

Y1 - 2022/6

N2 - The introduction of a third-dose vaccination along with new variants of concern raises questions regarding serology and T-cell responses in patients with multiple sclerosis (pwMS) treated with B-cell depletion who develop attenuated humoral response to vaccines. The aim of this study was to longitudinally evaluate humoral and cellular response to SARS-CoV-2 mRNA vaccine in ocrelizumab-treated pwMS before and following a third vaccine dose. Following the third vaccine dose, patients who are low or nonresponders following initial vaccination did not increase antibody titers. In healthy controls and ocrelizumab-treated pwMS, cellular response decreased 6 months after initial vaccination and increased significantly after the third dose. ANN NEUROL 2022;91:796–800.

AB - The introduction of a third-dose vaccination along with new variants of concern raises questions regarding serology and T-cell responses in patients with multiple sclerosis (pwMS) treated with B-cell depletion who develop attenuated humoral response to vaccines. The aim of this study was to longitudinally evaluate humoral and cellular response to SARS-CoV-2 mRNA vaccine in ocrelizumab-treated pwMS before and following a third vaccine dose. Following the third vaccine dose, patients who are low or nonresponders following initial vaccination did not increase antibody titers. In healthy controls and ocrelizumab-treated pwMS, cellular response decreased 6 months after initial vaccination and increased significantly after the third dose. ANN NEUROL 2022;91:796–800.

UR - http://www.scopus.com/inward/record.url?scp=85127001289&partnerID=8YFLogxK

U2 - 10.1002/ana.26343

DO - 10.1002/ana.26343

M3 - مقالة

C2 - 35243687

SN - 0364-5134

VL - 91

SP - 796

EP - 800

JO - Annals of Neurology

JF - Annals of Neurology

IS - 6

ER -

Severe Acute Respiratory Syndrome Coronavirus 2 Third Vaccine Immune Response in Multiple Sclerosis Patients Treated with Ocrelizumab

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this